UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

ST94037B

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Total Pages in this Submission

Docket No.

TO THE COMMISSIONER FOR PATENTS

Mail Stop Patent Application P.O. Box 1450 Alexandria, VA 22313-1450

	F CANCER TREATMENT BY p53 PROTEIN CONTROL	
		PT0
nd invented by	y:	⊃ 8 = 1
Serge CARII	LLO; Jean-Marie BLANCHARD and Marc PIECHACZYK	17302
a CONTINU	ATION APPLICATION, check appropriate box and supply the requisite information:	
☐ Continua	ation 🗵 Divisional 🗀 Continuation-in-part (CIP) of prior application No.:	09/405,920
Vhich is a: ⊠ Continua	ation Divisional Continuation-in-part (CIP) of prior application No.:	09/727 052
시 Continua Vhich is a:	ation U Divisional U Continuation-in-part (CIP) of prior application No.:	08/737,953
☐ Continua	ation Divisional Continuation-in-part (CIP) of prior application No.:	
Enclosed are:		
	Application Elements	· ·
1. 🗵 Fili	ing fee as calculated and transmitted as described below	
2. 🗵 Sp	ecification having 34 (1-34) pages and including the following:	
a. 🗵	Descriptive Title of the Invention	•
b. 🗆	Cross References to Related Applications (if applicable)	
c. 🗆	Statement Regarding Federally-sponsored Research/Development (if applicable)	
d. 🗵	Reference to Sequence Listing, a Table, or a Computer Program Listing Appendix	<
e. 🗵	Background of the Invention	
f. 🗵	Brief Summary of the Invention	
g. 🗵	Brief Description of the Drawings (if filed)	
h. 🗵	Detailed Description	
i. 🗵	Claim(s) as Classified Below	

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. ST94037B

Total Pages in this Submission

Application Elements (Continued)											
3.	X	Drawing(s) (when necessary as prescribed by 35 USC 113)									
	a.										
	b.	☐ Informal Number of Sheets									
4.	X	Oath or Declaration									
	a.	☐ Newly executed (original or copy) ☐ Unexecuted									
•	b.	☑ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)									
	C.	☐ With Power of Attorney ☐ Without Power of Attorney									
	d.	☐ <u>DELETION OF INVENTOR(S)</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).									
5.	\boxtimes	Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.									
6.		CD ROM or CD-R in duplicate, large table or Computer Program (Appendix)									
7.	\boxtimes	Application Data Sheet (See 37 CFR 1.76)									
8.	X	Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)									
	a.	☐ Computer Readable Form (CRF)									
	b.	Specification Sequence Listing on:									
		i. CD-ROM or CD-R (2 copies); or									
		ii. 🗵 Paper									
	C.	Statement(s) Verifying Identical Paper and Computer Readable Copy									
		Accompanying Application Parts									
9.		Assignment Papers (cover sheet & document(s))									
10.		37 CFR 3.73(B) Statement (when there is an assignee)									
11.		English Translation Document (if applicable)									
12.	\boxtimes	Information Disclosure Statement/PTO-1449 Copies of IDS Citations									
13.		Preliminary Amendment									
14.	\boxtimes	Return Receipt Postcard (MPEP 503) (Should be specifically itemized)									
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)									
16.		Certificate of Mailing									
		☐ First Class ☐ Express Mail (Specify Label No.):									

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. ST94037B

Total Pages in this Submission

		Accompanying Application Parts (Continued)
17.	\boxtimes	Additional Enclosures (please identify below):
		copies of PTO-1449 and PTO-892 filed in parent applications 09/405,920 and 08/737,953 (14 pages)
		Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)
18.		Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.
		Warning
		An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. ST94037B

Total Pages in this Submission

Fee Calculation and Transmittal

CLAIMS AS FILED											
For	#Filed	#Allowed	#Extra		Rate	Fee					
Total Claims	8	- 20 =	0	х	\$18.00	\$0.00					
ndep. Claims	1	- 3 =	0	x	\$86.00	\$0.00					
Multiple Dependent	Claims (check	if applicable)				\$0.00					
					BASIC FEI	\$770.00					
OTHER FEE (speci	OTHER FEE (specify purpose)										
					TOTAL FILING FEI	\$770.00					
as described bel Charge t Credit ar Charge t Charge t	he amount of my overpayment any additional file he issue fee set to 37 C.F.R. 1	\$ 770.00 t. ling fees required et in 37 C.F.R. 1.1	as filing fee. d under 37 C.F 18 at the mailin D	Credi R. 1.16 ng of the avid J. K	Notice of Allowance, Signature Kulik, Registration No. 36 REIN & FIELDING LLP						

cc:



Wiley Rein & Fielding LLP

1776 K STREET NW
WASHINGTON, DC 20006
PHONE 202.719.7000
FAX 202.719.7049

Virginia Office
7925 JONES BRANCH DRIVE
SUITE 6200
McLEAN, VA 22102
PHONE 703.905.2800
FAX 703.905.2820

www.wrf.com

March 1, 2004

David J. Kulik 202.719.7313 dkulik@wrf.com

VIA HAND DELIVERY

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Re: New Divisional Application

Claiming Priority to Serial No. 09/405,920, 08/737,953

And PCT/FR95/00670

Inventor: Serge CARILLO, et al.

Title: "Method of Cancer Treatment By p53

Protein Control"

Attorney Docket: ST94037A

Dear Sir:

Please accord the enclosed application a filing date and serial number. Applicants hereby claim priority to prior U.S. application nos. 09/405,920, and 08/737,953, which is the national phase of PCT/FR95/00670, the entire contents of which are incorporated herein by reference.

Please associate the Sequence Listing and computer readable format from parent application 09/405,920 with this new divisional application.

The following are attached:

- 1) Divisional Application Transmittal Form (4 pages);
- 2) Credit Card Payment Form (1 page);
- 3) Original specification

Specification (pages 1-34); including Sequence Listing and Abstract 1 Sheets of Formal Drawing, including Figs. 1a and 1b;

- 4) Executed Declaration (3 pages)
- 5) Copy of Submission of Sequence Listing submitted in prior application (9 pages)
- 6) Copies of Form PTO 1449 and PTO-892 from prior applications (14 pages)
- 7) Application Data Sheet (3 pages);

Wiley Rein & Fielding LLP

Commissioner of Patents March 1, 2004 Page 2

Postage-paid return receipt postcard for advance notification of application number.

Respectfully submitted,

David J. Kulik, Esq. Reg. No. 36,576

WRFMAIN 12177292.1